{
  "abstract": "Background\n\nRadiological response dynamics may provide prognostic information beyond conventional response categories in patients with unresectable hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab. Building upon findings from the IMbrave150 trial, we evaluated the prognostic significance of depth of response (DpR), duration of response (DoR), and time to response (TTR) in a real-world cohort.Methods\n\nThis retrospective multicenter study included 183 treatment-naïve patients with unresectable HCC treated with atezolizumab plus bevacizumab between November 2020 and September 2024. Tumor response was assessed according to mRECIST. Associations of DpR, DoR, and TTR with overall survival (OS) and progression-free survival (PFS) were evaluated using landmark analyses and time-dependent Cox analyses.Results\n\nDeeper tumor response, longer DoR, and ≥50% reductions in serologic biomarker correlated with improved survival. Patients who achieved an early response (≤2 months) tended to have less favorable survival outcomes than those with a later response. Multivariate analysis confirmed DoR (HR = 0.40; 95% CI: 0.30-0.55; p < 0.001) and DpR (HR = 0.45; 95% CI: 0.38-0.55; p < 0.001) as independent predictors for improved OS, while early response independently predicted worse OS (HR = 1.64; 95% CI: 1.26-2.15; p < 0.001). Similar trends were observed for PFS. Exploratory analyses suggested a potential association between conversion surgery and prolonged OS.Conclusion\n\nDpR and DoR were independently associated with survival outcomes in patients with unresectable HCC receiving atezolizumab plus bevacizumab, extending and validating previous findings from IMbrave150 in a real-world setting. The prognostic significance of TTR and conversion surgery warrants further prospective investigation.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Hepatobiliary Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.",
    "Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.",
    "State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.",
    "Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Renguo Guan"
    },
    {
      "affs": [
        0
      ],
      "name": "Kaijun Huang"
    },
    {
      "affs": [
        1,
        2,
        3
      ],
      "name": "Zehao Zheng"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhen Zhao"
    },
    {
      "affs": [
        0
      ],
      "name": "Meishi Tang"
    },
    {
      "affs": [
        0
      ],
      "name": "Haosheng Jin"
    },
    {
      "affs": [
        1,
        2,
        3
      ],
      "name": "Jie Mei"
    },
    {
      "affs": [
        0
      ],
      "name": "Ye Lin"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/fg7pxfwpyrvk1.bib",
  "cited_by": 0,
  "doi": "10.1159/lic/admag002",
  "fulltext_url": "https://europepmc.org/articles/PMC13688699",
  "id": "fg7pxfwpyrvk1",
  "issns": [
    "2235-1795",
    "1664-5553"
  ],
  "landing_url": "https://europepmc.org/article/MED/42924060",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2721|Hepatocellular Carcinoma Treatment and Prognosis"
    ]
  ],
  "openalex": "W7203680708",
  "pdf_url": "https://europepmc.org/articles/PMC13688699?pdf=render",
  "pmcid": "PMC13688699",
  "pmid": "42924060",
  "published": "2026-07-30",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/fg7pxfwpyrvk1.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:02Z",
      "native_id": "MED:42924060",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42924060"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2721|Hepatocellular Carcinoma Treatment and Prognosis",
      "subfield": "general"
    }
  ],
  "title": "Prognostic Significance of Response Dynamics in Atezolizumab plus Bevacizumab-Treated Hepatocellular Carcinoma: A Multicenter Real-World Validation Study.",
  "title_text": "Prognostic Significance of Response Dynamics in Atezolizumab plus Bevacizumab-Treated Hepatocellular Carcinoma: A Multicenter Real-World Validation Study.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:02Z",
  "url": "https://research.draconitic.com/paper/fg7pxfwpyrvk1",
  "venue": "Liver cancer",
  "versions": []
}